Yabao Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include Chinese and Western medicine preparations, patches, active pharmaceutical ingredients and pharmaceutical packaging materials. The Company's products mainly involve pediatrics, adult medicines and health products. The Company sells its products under the brands of Yabao, Dinggui, Yabao Lishu and Yabao Weiyuan. The Company mainly operates its businesses in the domestic and overseas markets.

Employees

3,415

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	CN¥6.260	+2.79%	15,588,946
09/07/26	CN¥6.090	-0.65%	11,289,800
08/07/26	CN¥6.130	0.00%	9,270,500
07/07/26	CN¥6.130	-2.39%	11,653,200
06/07/26	CN¥6.280	+1.29%	16,951,900

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shanghai S.E. Other stock markets 10/07/2026			5-day change	1st Jan Change
6.260 ^CNY	+2.79%		+0.97%	-3.54%

05-25	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	4.33B 639M 561M 518M 477M 905M 60.97B 921M 6.18B 2.42B 29.91B 2.4B 2.35B 103B	P/E 2024	18.1x	P/E 2025	14.2x
Enterprise Value	3.55B 524M 459M 424M 391M 741M 49.93B 754M 5.06B 1.98B 24.49B 1.97B 1.92B 84.72B	EV / Sales 2024	1.45x	EV / Sales 2025	1.65x
Free-Float	79.86%	Yield 2024	4.93%	Yield 2025	5.39%

05-25	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12-22	Shanxi Tongxiang Times Technology Co., Ltd. completed the acquisition ofan additional 62% stake in Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. from Yabao Pharmaceutical Group Co., Ltd.	CI
12-18	Yabao Pharma Gets Clinical Trial Nod for Pulmonary Arterial Hypertension Drug	MT
11-17	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI
11-14	Yabao Pharmaceutical Group Co., Ltd's Equity Buyback announced on May 17, 2025, has closed with 8,000,000 shares, representing 1.14% for CNY 52.15 million.	CI
11-13	Yabao Pharmaceutical Obtains Registration for Children's Nutrition Product	MT
24/10/25	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/10/25	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI
24/09/25	Yabao Pharmaceutical Gets Nod to Trial Asthma Drug for Children	MT
23/09/25	Yabao Pharmaceutical Ends Trial for Diabetes Drug; Shares Down 3%	MT
15/08/25	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI

30/06/16	Yabao Pharmaceutical : Pharmaceuticals and LFB Biomedicaments Enter Into Strategic Partnership to Deliver VIALEBEX® (LFB’s Human Albumin) in China	BU
20/04/16	Yabao Pharmaceutical : Pharmaceuticals and Salus Pharma Announce Strategic Partnership for Generic Drugs	BU
12/01/16	Yabao Pharmaceuticals : and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China	BU
20/10/15	Yabao Pharmaceuticals : Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment	BU
15/09/15	Yabao Pharmaceuticals : and Primary Peptides Announce Exclusive China Partnership	BU

Yabao Pharmaceutical Group Co., Ltd Stock

Stocks

600351

CNE000001CM5

Pharmaceuticals

Valuation: Yabao Pharmaceutical Group Co., Ltd

Chart: Yabao Pharmaceutical Group Co., Ltd

Latest news : Yabao Pharmaceutical Group Co., Ltd

Press Releases: Yabao Pharmaceutical Group Co., Ltd

News in other languages: Yabao Pharmaceutical Group Co., Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Yabao Pharmaceutical Group Co., Ltd

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+2.79%
1 week	+0.97%
Current month	+8.87%
1 month	+0.97%
3 months	-6.85%
6 months	-6.01%
Current year	-3.54%

1 week	6	6.34
1 month	5.6	6.34
Current year	5.6	7.19
1 year	5.6	8.68
3 years	4.94	9
5 years	4.94	11.9
10 years	4.5	11.9

Manager	Title	Age	Since
Wei Ren CEO	Chief Executive Officer	42	23/04/2019
Zhe Feng Zuo DFI	Director of Finance/CFO	54	17/05/2017
Peng Bo Ren PRN	Corporate Officer/Principal	53	11/03/2007

Director	Title	Age	Since
Wu Xian Ren CHM	Chairman	66	26/05/2005
Min Xuan Cui BRD	Director/Board Member	66	16/06/2020
Peng Bo Ren BRD	Director/Board Member	53	15/05/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
YABAO PHARMACEUTICAL GROUP CO., LTD	+2.79%	+0.97%	-0.63%	-12.93%	639M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.17%	+1.61%	+15.76%	+80.51%	48.69B
OTSUKA HOLDINGS CO., LTD.	+1.04%	-1.02%	+67.19%	+116.18%	36.38B
CIPLA LIMITED	-0.13%	-1.29%	-3.07%	+40.05%	12.19B
ZYDUS LIFESCIENCES LIMITED	-0.71%	+0.89%	+17.48%	+96.77%	12.04B
KRKA, D. D.	-0.76%	+0.38%	+31.49%	+124.03%	9.04B
GEDEON RICHTER	+0.75%	-0.82%	+18.53%	+42.99%	7.09B
ONO PHARMACEUTICAL CO., LTD.	-0.86%	+0.37%	+50.57%	-3.02%	7.06B
GLENMARK PHARMACEUTICALS LIMITED	+0.69%	+3.25%	+4.67%	+240.43%	6.75B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+5.45%	-7.36%	-17.51%	+14.39%	6.1B
Average	+0.81%	-0.41%	+18.45%	+73.94%	14.6B
Weighted average by Cap.	+0.35%	+0.09%	+27.96%	+88.41%

	2024	2025
Net sales	2.69B 396M 348M 321M 296M 561M 37.8B 571M 3.83B 1.5B 18.55B 1.49B 1.46B 64.15B	2.24B 331M 290M 268M 247M 468M 31.53B 476M 3.2B 1.25B 15.47B 1.24B 1.21B 53.5B
Net income	243M 35.82M 31.41M 28.99M 26.75M 50.72M 3.42B 51.59M 346M 136M 1.68B 134M 132M 5.8B	320M 47.23M 41.41M 38.23M 35.27M 66.88M 4.5B 68.03M 456M 179M 2.21B 177M 173M 7.64B
Net Debt	-483M -71.26M -62.49M -57.69M -53.22M -101M -6.8B -103M -689M -270M -3.33B -268M -262M -11.53B	-784M -116M -102M -93.71M -86.45M -164M -11.04B -167M -1.12B -438M -5.42B -435M -425M -18.73B